Loading
A phase 2 trial of Human BCMA Targeted T Cells Injection in multiple myeloma, run by Hrain Biotechnology Co., Ltd., now recruiting.
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM is a phase 2 interventional study registered as NCT05594797 by Hrain Biotechnology Co., Ltd., with 100 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-07-31. Interventions recorded: Human BCMA Targeted T Cells Injection.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.